BAJAJ BROKING

Notification close image
No new Notification messages
card image
Anondita Medicare IPO is Open!
Apply for the Anondita Medicare IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

540359

PARMAX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Parmax Pharma Limited Share Price Update

As of the latest trading session, Parmax Pharma Limited share price is currently at ₹ 36.79, which is up by ₹ 0.37 from its previous closing. Today, the stock has fluctuated between ₹ 34.50 and ₹ 36.80. Over the past year, Parmax Pharma Limited has achieved a return of 3.51 %. In the last month alone, the return has been -7.27 %. Read More...

Investment Returns

Over 1 Month -7.27% Over 3 Months -18.58% Over 6 Months -14.73% Over 1 Year 3.51%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Parmax Pharma Limited fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    13.80

  • P/E Ratio (TTM)

    -4.80

  • Beta

    -0.18

  • Book Value / share

    -7.21

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    -0.76

info icon alternate text

Parmax Pharma Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 1.94
Operating Expense 2.71
Net Profit -0.76
Net Profit Margin (%) -39.17
Earnings Per Share (EPS) -2.04
EBITDA -0.24
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 4.83
Operating Expense 5.45
Net Profit -1.49
Net Profit Margin (%) -30.84
Earnings Per Share (EPS) -4.00
EBITDA -1.74
Effective Tax Rate (%) 16.66
Particulars DEC 2024 (Values in Cr)
Revenue 6.28
Operating Expense 6.70
Net Profit -0.39
Net Profit Margin (%) -6.21
Earnings Per Share (EPS) -1.05
EBITDA 0.12
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 9.28
Operating Expense 9.61
Net Profit -0.22
Net Profit Margin (%) -2.37
Earnings Per Share (EPS) -0.58
EBITDA 0.31
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 7.82
Operating Expense 7.81
Net Profit 0.01
Net Profit Margin (%) 0.12
Earnings Per Share (EPS) 0.03
EBITDA 0.52
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 28.20
Operating Expense 29.57
Net Profit -2.09
Net Profit Margin (%) -7.41
Earnings Per Share (EPS) -5.60
EBITDA -0.78
Effective Tax Rate (%) 12.50
Particulars MAR 2024 (Values in Cr)
Revenue 11.05
Operating Expense 16.76
Net Profit -5.75
Net Profit Margin (%) -52.03
Earnings Per Share (EPS) -15.37
EBITDA -3.33
Effective Tax Rate (%) -1.59
Particulars MAR 2023 (Values in Cr)
Revenue 15.42
Operating Expense 15.42
Net Profit -0.10
Net Profit Margin (%) -0.64
Earnings Per Share (EPS) -0.28
EBITDA 2.30
Effective Tax Rate (%) 299.99
Particulars MAR 2022 (Values in Cr)
Revenue 18.25
Operating Expense 18.01
Net Profit 0.14
Net Profit Margin (%) 0.76
Earnings Per Share (EPS) 0.38
EBITDA 2.62
Effective Tax Rate (%) 53.33
Particulars MAR 2021 (Values in Cr)
Revenue 26.20
Operating Expense 25.08
Net Profit 0.75
Net Profit Margin (%) 2.86
Earnings Per Share (EPS) 2.02
EBITDA 3.50
Effective Tax Rate (%) 37.19
Particulars MAR 2024 (Values in Cr)
Book Value / Share 0.16
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.91
EBITDA Margin -30.05
Particulars MAR 2023 (Values in Cr)
Book Value / Share 13.16
ROE % -1.69
ROCE % 3.76
Total Debt to Total Equity 0.89
EBITDA Margin 14.85
Particulars MAR 2022 (Values in Cr)
Book Value / Share 13.39
ROE % 2.38
ROCE % 6.04
Total Debt to Total Equity 0.94
EBITDA Margin 14.41
Particulars MAR 2021 (Values in Cr)
Book Value / Share 13.07
ROE % 13.79
ROCE % 14.26
Total Debt to Total Equity 1.02
EBITDA Margin 13.44
Particulars MAR 2020 (Values in Cr)
Book Value / Share 11.38
ROE % 8.88
ROCE % 8.40
Total Debt to Total Equity 1.11
EBITDA Margin 8.93
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 15.33
Total Liabilities 15.33
Total Equity 0.07
Share Outstanding 5100800
Price to Book Ratio 178.00
Return on Assets (%) -37.69
Return on Capital (%) -96.68
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.40
Total Assets 17.61
Total Liabilities 17.61
Total Equity 5.85
Share Outstanding 44512
Price to Book Ratio 2.31
Return on Assets (%) -0.59
Return on Capital (%) -1.01
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.05
Total Assets 17.97
Total Liabilities 17.97
Total Equity 5.95
Share Outstanding 4451150
Price to Book Ratio 3.05
Return on Assets (%) 0.78
Return on Capital (%) 1.35
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.54
Total Assets 22.72
Total Liabilities 22.72
Total Equity 5.81
Share Outstanding 4451150
Price to Book Ratio 2.72
Return on Assets (%) 3.31
Return on Capital (%) 6.7
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.76
Total Assets 21.06
Total Liabilities 21.06
Total Equity 5.06
Share Outstanding 4451150
Price to Book Ratio 0.00
Return on Assets (%) 2.03
Return on Capital (%) 4.25
Particulars MAR 2024 (Values in Cr)
Net Income -5.65
Cash from Operations -0.19
Cash from Investing -1.58
Cash from Financing 1.42
Net change in Cash -0.34
Free Cash Flow 1.29
Particulars MAR 2023 (Values in Cr)
Net Income 0.04
Cash from Operations 0.33
Cash from Investing -0.93
Cash from Financing -0.04
Net change in Cash -0.64
Free Cash Flow 1.26
Particulars MAR 2022 (Values in Cr)
Net Income 0.30
Cash from Operations 0.74
Cash from Investing -1.53
Cash from Financing -0.91
Net change in Cash -1.69
Free Cash Flow 2.28
Particulars MAR 2021 (Values in Cr)
Net Income 1.20
Cash from Operations 3.52
Cash from Investing -3.14
Cash from Financing 0.39
Net change in Cash 0.77
Free Cash Flow 6.67
Particulars MAR 2020 (Values in Cr)
Net Income 0.73
Cash from Operations 2.82
Cash from Investing -2.39
Cash from Financing -0.22
Net change in Cash 0.20
Free Cash Flow 5.22
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.22 13.97 1.87 262.24 30.00 / 69.75
BLISS GVS PHARMA LTD 166.55 16.47 1.67 1757.06 105.05 / 190.65
CIPLA LTD 1545.85 23.16 4.00 124866.66 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 342.40 9.64 2.77 1007.72 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2785.40 49.83 24.18 47186.36 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.22 18.60 5.40 262.24 30.00 / 69.75
AMRUTAJAN HEALTH LTD 722.05 38.28 6.39 2087.49 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8450.65 99.90 27.42 21126.63 6222.35 / 10653.05
BLISS GVS PHARMA LTD 166.55 24.90 1.65 1757.06 105.05 / 190.65

Parmax Pharma Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
36.79 1.01 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 37.00
  • 26 Days 38.10
  • 10 Days 37.30
  • 50 Days 39.10
  • 12 Days 37.40
  • 100 Days 40.30
  • 20 Days 37.90
  • 200 Days 40.60
37.65 PIVOT

First Support

35.30

First Resistance

39.72

Second Support

33.23

Second Resistance

42.07

Third Support

30.88

Third Resistance

44.14

RSI

47.76

ADX

9.90

MACD

-0.66

Williams % R

-53.24

Commodity Channel Index (CCI)

-34.83

Date

2025-08-20

Week

2488.00

Same Day

5736.00

Month

2040.00

1 Year

-0.19

3 Year

0.13

Over 1 Month

-7.27%

down

Over 1 Year

3.51%

down

Over 3 Months

-18.58%

down

Over 3 Years

6.42%

down

Over 6 Months

-14.73%

down

Over 5 Years

-0.12%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Parmax Pharma Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

Parmax Pharma Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Parmax Pharma Limited Share Price

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.

The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May'97.

Parent organization Indian Private
NSE symbol [-]
Founded 1994
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Parmax Pharma Ltd?

Answer Field

Parmax Pharma Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 36.79 as on Aug 22 2025 02:37 PM.

What is the Market Cap of Parmax Pharma Ltd Share?

Answer Field

The market cap of Parmax Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 13.80 as on Aug 22 2025 02:37 PM.

What is the 52 Week High and Low of Parmax Pharma Ltd?

Answer Field

The 52 Week High and Low of Parmax Pharma Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 55.02 and ₹ 31.50.

What is 1 year return for Parmax Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 8.17%.

What is the P/E Ratio of Parmax Pharma Ltd Share?

Answer Field

As on Aug 22 2025 02:37 PM the price-to-earnings (PE) ratio for Parmax Pharma Ltd share is -4.80.

What is the PB ratio of Parmax Pharma Ltd Share?

Answer Field

As on Aug 22 2025 02:37 PM, the price-to-book (PB) ratio for Parmax Pharma Ltd share is -7.21.

How to Buy Parmax Pharma Ltd Share?

Answer Field

You can trade in Parmax Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Parmax Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Parmax Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Parmax Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91